Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$287.36 USD
+4.04 (1.43%)
Updated Oct 15, 2024 04:00 PM ET
After-Market: $287.52 +0.16 (0.06%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth D Momentum F VGM
Price, Consensus and EPS Surprise
ALNY 287.36 +4.04(1.43%)
Will ALNY be a Portfolio Killer in October?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for ALNY
VNDA Rejects Second Takeover Bid by Cycle Group, Stock Rises
Longboard Set to be Acquired by Lundbeck for $2.6B, Stock Soars 52%
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
RPTX Stock Up as Dosing Begins in Solid Tumor Study for Combo Drug
Exelixis, MRK Collaborate for Combination Studies on HNSCC and RCC
PTCT Stock Rises on Positive Updates on Friedreich Ataxia Program
Other News for ALNY
Alnylam price target raised by $7 at BofA, here's why
$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Allakos (ALLK) and Tempest Therapeutics (TPST)
Hold Rating on Alnylam Pharmaceuticals Amid Vutrisiran Commercialization Challenges
Alnylam Pharma (ALNY) Receives a Buy from Jefferies